[Corrigendum] Genistein exerts growth inhibition on human osteosarcoma MG-63 cells via PPARγ pathway

Figure 1

The human osteosarcoma MG-63 cell growth inhibition by genistein, GW9662 and their combination: (A) the effects of various doses of genistein on the viability of MG-63 cells after 24, 48 and 72 h; (B) the effects of various doses of GW9662 on the viability of MG-63 cells after 24, 48 and 72 h; (C) the effects of various doses of genistein with 1 μmol/l of GW9662 on the viability of MG-63 cells after 48 h. The total percentage of viable cells was measured by CCK-8 assay. Data are expressed as mean ± SD in three independent experiments. Bars marked with asterisks are significant with respect to the controls at *P<0.05 and **P<0.01. The number of viable cells significantly increased, compared with the relative genistein group (#P<0.05). EdU assay of relative Hoechst stained cells and EdU add-in cells. (D) MG-63 cells were treated with different concentrations of genistein, combination or control. Forty-eight hours after treatment, EdU (100 μmol/l) was added and the cells were cultured for 2 h. EdU and Hoechst staining were performed, as described in Materials and methods. At least 200 cells were counted per well. (E) Data are expressed as mean ± SD in the representative experiments performed in triplicate. The proliferation rate of MG-63 cells, treated with different concentrations of genistein or the combined group, significantly decreased compared with the control (*P<0.05). The proliferation rate of the combination group significantly increased, compared with the relative genistein group (#P<0.05).